LB Pharmaceuticals IncNASDAQ: LBRX

LB Pharmaceuticals to Participate in Upcoming September Investor Events

· Issued by LB Pharmaceuticals Inc via GlobeNewswire

Summary by 6ix AI

LB Pharmaceuticals, a company developing medicines for brain disorders, said members of its executive team will present and take part in three investor conferences between September 9, 2026 and September 23, 2026.

Key details

  • Wells Fargo 21st Annual Healthcare Conference: one-on-one investor meetings on Wednesday, September 9, 2026, in Boston, MA.
  • H.C. Wainwright 28th Annual Global Investment Conference: a presentation available virtually at 10:00 a.m. ET on Monday, September 14, 2026, plus virtual one-on-one investor meetings the same day.
  • TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit: a virtual fireside chat (an informal question-and-answer session) at 2:30 p.m. ET on Wednesday, September 23, 2026.
  • Webcasts of the presentation and fireside chat will be available in the Events section of the Investors page on the company's website, where replays will be archived.

6ix AI wrote this summary from the release below and checked it against the release.

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team, will present and participate in the following upcoming investor conferences:

Wells Fargo 21st Annual Healthcare Conference

  • 1x1 investor meetings on Wednesday, September 9, 2026, in Boston, MA

H.C. Wainwright 28th Annual Global Investment Conference

  • Presentation will be available virtually at 10:00 a.m. ET on Monday, September 14, 2026

  • Virtual 1x1 investor meetings on Monday, September 14, 2026

TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit

  • Virtual fireside chat at 2:30 p.m. ET on Wednesday, September 23, 2026

The webcasts for the presentation and fireside chat will be available on the "Investors" page section under the "Events" section of the Company's website at https://ir.lbpharma.us/, where a replay of the webcasts will be archived.

About LB Pharmaceuticals
LB Pharmaceuticals is a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.

Media and Investor Contact:
Ellen Rose
[email protected]

LB Pharmaceuticals Inc on 6ix

Story so far

Earlier from LB Pharmaceuticals

Later from LB Pharmaceuticals

All LB Pharmaceuticals news releases